Organogenesis Inc., a leading regenerative medicine company headquartered in the United States, has been at the forefront of innovation since its founding in 1985. Specialising in advanced wound care and surgical biologics, the company operates primarily in the US, with a growing presence in international markets. Known for its unique portfolio of products, including Apligraf® and Dermagraft®, Organogenesis focuses on providing solutions that promote healing and tissue regeneration. These products stand out due to their ability to harness the body’s natural healing processes, making them essential in the treatment of chronic wounds and surgical applications. With a strong market position, Organogenesis has achieved significant milestones, including numerous FDA approvals and recognition for its commitment to quality and efficacy in regenerative therapies. The company continues to lead the industry, driving advancements that improve patient outcomes and enhance the standard of care.
We don't have data for Organogenesis Inc., but we can show you information about their parent organization instead.
View parent company